Navigation Links
PharmAthene Reports Third Quarter 2009 Financial and Operational Results
Date:11/12/2009

combinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) - a recombinant dual antigen vaccine for plague
  • For more information about PharmAthene, please visit www.PharmAthene.com.

    Statement on Cautionary Factors

    Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the DHHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
    2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
    3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
    4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
    5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
    6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
    7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
    8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
    9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
    10. PharmAthene to Delay Release of Full Year 2007 Financial Results
    11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/27/2014)... Massachusetts, USA (PRWEB) November 26, 2014 ... more accuracy, additive systems to enable 3D manufacture at ... analyzing road conditions are among finalists in nine categories ... . The awards are sponsored by SPIE, the ... Photonics Media . , Winners will be announced by ...
    (Date:11/26/2014)... In keeping with the holiday spirit, DNA ... Thanksgiving savings. The company is offering up a variety ... this holiday weekend as well as a photo contest ... Monday are right around the corner, and DNA Spectrum ... and those looking to explore their ancestry, health, and ...
    (Date:11/26/2014)... 2014 The ETC (Emerging Technology ... innovation centers, announced today that applications for AccelerateBaltimore™ ... 1st. “Do you have a big idea?,” asked ... to know about it. AccelerateBaltimore helps you and ... in just 13 weeks.” Interested game changers ...
    (Date:11/26/2014)... 2014 Continuing its award-winning streak, Nerium ... prestigious MarCom Awards for outstanding creative achievement by its ... MarCom Award, the organization’s top honor, in the Branding ... held in April of this year. The event showcased ... Additionally, Nerium was awarded a Gold MarCom Award in ...
    Breaking Biology Technology:Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3AccelerateBaltimore Applications to Close in 6 Days 2AccelerateBaltimore Applications to Close in 6 Days 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2
    ... FRANCISCO, March 11 VIA Pharmaceuticals,(Nasdaq: VIAP ... of,compounds for the treatment of cardiovascular disease, announced ... James G. Stewart, senior,vice president and chief financial ... Cowen and Company 28th Annual Health Care Conference ...
    ... Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ), a clinical-stage ... of,novel small-molecule therapeutics, today reported financial results for ... Total revenue for the fourth quarter of ... $8.8 million. Total revenue for the year ended ...
    ... N.J., March 11 Pharmacopeia,(Nasdaq: PCOP ), an ... therapeutics, today announced that Dr. Leslie J. Browne,President and ... Cowen and Company 28th Annual Health Care Conference.,The conference ... The Boston Marriott,Copley Place, Boston, Massachusetts., Dr. Browne,s ...
    Cached Biology Technology:Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 2Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 3Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 4Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 5Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 6Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 7Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 8Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 9Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 10Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference 2Pharmacopeia to Present at the Cowen and Company 28th Annual Health Care Conference 3
    (Date:11/3/2014)... from Australia report that low birth weight and preterm ... hip replacements in adulthood. Findings published in the American ... Research , indicate that low birth weight and pre-term ... due to OA as adults. , According to ... 25 are diagnosed with clinical OA. Symptoms of OA ...
    (Date:11/2/2014)... (2 November 2014)—In support of a bold quest to ... Melinda Gates Foundation today announced an award of US$156 ... Initiative (MVI) in building new vaccines that will interrupt ... the "accelerating to zero" agenda. Such vaccines would ensure ... be called an "immunological bed net." , This ...
    (Date:11/2/2014)... a bar and bump into a biologist . . . ... late-night nerd sketch, researchers have taken this premise and applied ... finding meaning in the rising oceans of genomic data. , ... that genome-wide studies are publishing at a dizzying rate. The ... signal from the noise (and there is no shortage of ...
    Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
    ... patients miserable and debilitated with chronic itching or pain ... possible paralysis or damage to the brain and other ... effective treatment even though the responsible gene was identified ... done to treat a disease that affects more people ...
    ... have identified a specific protein molecule that is used ... leading the way for development of future vaccines to ... issue of Science Express, the study provides insight into ... problem of great scientific and clinical importance. , Most ...
    ... field trials in China report higher crop yields, reduced ... a study by researchers in China and at Rutgers ... of the study will appear in the April 29 ... two of the four GM varieties that are now ...
    Cached Biology News:Potential treatments for neurofibromatosis 2Potential treatments for neurofibromatosis 3Yale researchers identify molecule for detecting parasitic infection in humans 2Genetically modified rice in China benefits farmers' health, study finds 2Genetically modified rice in China benefits farmers' health, study finds 3Genetically modified rice in China benefits farmers' health, study finds 4